What insurance policy changes affect CPT 92588?

There are 5 tracked policy changes affecting CPT 92588, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 92588?

Payers that have issued tracked updates for CPT 92588 include: Aetna.

How do I get notified when CPT 92588 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 92588. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 92588?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

92588 — A comprehensive hearing test that measures how your ears and brain respond to sound signals.: Insurance Policy Changes

92588 Insurance Policy Changes

CPT 92588, in plain terms, covers A comprehensive hearing test that measures how your ears and brain respond to sound signals. CPT 92588 is referenced in 5 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 92588 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medium impact

Electrocochleogram and Perilymphatic Pressure Measurement (CPB 0564, reviewed 2026-07-30)

Aetna·Effective Jul 30, 2026

Aetna updated its medical policy on electrocochleography (CPT 92584) to clarify coverage criteria. The procedure is now covered ONLY when used for: (1) evaluation of episodic dizziness/vertigo/tinnitus to rule out Meniere's disease or perilymphatic fistula, or (2) when performed with ABR testing in patients with profound hearing loss (PTA ≥90 dB HL). Multiple other indications—including pre-implantation counseling, routine screening, intraoperative use during cochlear implant surgery, and perilymphatic pressure measurement—are explicitly classified as experimental/investigational and NOT covered.

92588 Insurance Policy Changes

Lunsotogene Parvec-cwha (Otarmeni) (CPB 1103, reviewed 12-2026-08)

Auditory Processing Disorder (APD) (CPB 0668, reviewed 2025-10-07)

Electrocochleogram and Perilymphatic Pressure Measurement (CPB 0564, reviewed 2026-07-30)

Auditory Processing Disorder (APD) (CPB 0668, reviewed 2026-10-07)

Lunsotogene Parvec-cwha (Otarmeni) (CPB 1103)